88
Views
0
CrossRef citations to date
0
Altmetric
Special Report

Opioid Maintenance, Weaning and Detoxification Techniques: Where We have been, Where We are Now and What the Future Holds

, , &
Pages 277-284 | Published online: 03 Jul 2013

References

  • Doyon S . Opioids. In: Emergency Medicine: A Comprehensive Study Guide (6th Edition). Tintinalli JE, Kelen GD, Stapczynski JS, Ma OJ, Cline DM (Eds). McGraw-Hill, NY, USA, 1071–1075 (2004).
  • Fishbain DA , RosomoffHL, RosomoffRS. Drug abuse, dependence, and addiction in chronic pain patients. Clin. J. Pain8 , 77–85 (1992).
  • Chelminski PR , IvesTJ, FelixKM et al. A primary care, multi-disciplinary disease management program for opioid-treated patients with chronic non-cancer pain and a high burden of psychiatric comorbidity. BMC Health Serv. Res. 5(1) , 3 (2005).
  • Dumas EO , PollackGM. Opioid tolerance development: a pharmacokinectic/pharmacodynamic perspective. AAPS J.10 , 537–551 (2008).
  • Rothman RB , LongJB, BykovV et al. Upregulation of the opioid receptor complex by the chronic administration of morphine: a biochemical marker related to the development of tolerance and dependence. Peptides 12 , 151–160 (1991).
  • Tao PL , ChangLR, ChouYP et al. Chronic opioid treatment may uncouple opioid receptors and G-proteins: evidence from radiation inactivation analysis. Eur. J. Pharm. 246 , 233–238 (1993).
  • Angres DH , Bettinardi-AngresK. The disease of addiction: origins, treatment, and recovery. Dis. Mon.10 , 696–721 (2008).
  • Rogak LJ , StarrTD, KirshKL, PassikSD. The psychology of addiction. In: Bonica‘s Management of Pain (4th Edition). Fishman SM, Ballantyne JC, Rathmell JP (Eds). Lippincott Williams and Wilkins, PA, USA, 418–422 (2010).
  • Saunders JB , SchuckitMA. The development of a research agenda for substance use disorders diagnosis in the Diagnostic and Statistical Manual of mental disorders (5th Edition) (DSM-V). Addiction101(Suppl. 1) , S1–S5 (2006).
  • Torrens M , CastilloC, SanL et al. Plasma methadone concentrations as an indicator of opioid withdrawal symptoms and heroin use in a methadone maintenance program. Drug Alcohol Depend. 52 , 193–200 (1998).
  • Dijkstra BA , KrabbePF, De Jong CA et al. Prediction of withdrawal symptoms during opioid detoxification. J. Opioid Manag.4 , 311–319 (2008).
  • Margolin A , KostenTR. Opioid detoxification and maintenance with blocking agents. In: Comprehensive Handbook of Drug and Alcohol Addiction. Miller NS (Ed.). Marcel Decker, NY, USA, 1127–1144 (1991).
  • Mattick RP , HallW. Are detoxification programmes effective? Lancet347 , 97–100 (1996).
  • Institute of Medicine. The effectiveness of treatment. In: Treating Drug Problems (Volume 1). Gertstein D, Harwood H (Eds). National Academy Press, Washington DC, USA, 132–199 (1990).
  • Gowing LR , AliRL, WhiteJM. The management of opioid withdrawal. Drug Alcohol Rev.19 , 309–318 (2000).
  • Cuskey WR , ChambersCD, WielandWF. Predicting attrition during the outpatient detoxification of narcotic addicts. Med. Care.9 , 108–116 (1971).
  • Warden D , SubraniamGA, CarmodyT et al. Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth. Addict. Behav. 37 , 1046–1053 (2012).
  • Rodriquez M , StoyanovaA. [The influence of the type of insurance access on health and of education on health services utilization patterns]. Gac. Sanit.18 , 102–111 (2004).
  • Ahmed S , CreanqaAA, GillespieDG et al. Economic status, education and empowerment: implications for maternal health service utilization in developing countries. PLoS ONE 5(6) , e11190 (2010).
  • Christie JM . Opioid prescribing: methadone risk mitigation. Anesthes. Patient Saf. Foundation Newslett.26(1) , 1–15 (2011).
  • Joseph H , StancliffS, LangrodJ. Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J. Med.67(5–6) , 347–364 (2000).
  • Faggiano F , Vigna-TagliantiF, VersinoE, LemmaP. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst. Rev.3 , CD002208 (2003).
  • Donny EC , BrasserSM, BigelowGE, StitzerML, WalshSL. Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction100(10) , 1496–1509 (2005).
  • Johnson RE , ConeEJ, HenningfieldJE et al. Use of buprenorphine in the treatment of opiate addiction. Clin. Pharm. Ther. 46 , 335–342 (1989).
  • Bickel WK , AmassL. Buprenorphine treatment of opioid dependence: a review. Exp. Clin. Psych.4 , 477–489 (1995).
  • Strain EC , StitzerML, LiebsonIA et al. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am. J. Psychiatry 151(7) , 1025–1030 (1994).
  • Ling W , CharuvastraC, CollinsJF et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 93(4) , 475–486 (1998).
  • Fudala PJ , JaffeJH, DaxEM. Use of buprenorphine in the treatment of opioid addiction II: physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. J. Clin. Pharm. Ther.47 , 525–534 (1990).
  • Perry NM , BickelWK, BadgerGJ. A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence. Clin. Pharmacol. Ther.66 , 306–314 (1999).
  • Ling W , AmassL, ShoptawS et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute of Drug Abuse Clinical Trials Network. Addiction 100(8) , 1090–1100 (2005).
  • Kosten TR , SchottenfeldR, ZiedonisD, FalcioniJ. Buprenorphine versus methadone maintenance for opioid dependence. J. Nervous Mental Dis.181(6) , 358–364 (1993).
  • Mattick RP , KimberJ, BreenC, DavoliM. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev. (2) , CD002207 (2008).
  • Ling W , HillhouseM, DomierC et al. Buprenorphine tapering schedule and illicit opioid use. Addiction 104(2) , 256–265 (2009).
  • Gowing L , AliR, WhiteJM. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst. Rev. (3) , CD002025 (2009).
  • Marsch LA , BickelWK, BadgerGJ et al. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch. Gen. Psychiatry 62 , 1157–1164 (2005).
  • Johnson RE , ChutuapeMA, StrainEC, WalshSL, StitzerML, BigelowGE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N. Engl. J. Med.343 , 1290–1297 (2000).
  • Suboxone®, prescribing information. Reckitt Benckiser Pharmaceuticals, Inc., VA, USA (2010).
  • Tetrault JM , O‘ConnorPG. Substance abuse and withdrawal in the critical care setting. Crit. Care Clin.24 , 767–788 (2008).
  • Freedman RR , CzertkoG. A comparison of thrice weekly LAAM and daily methadone in employed heroin addicts. Drug Alcohol Depend.8 , 215–222 (1981).
  • Clark N , LintzerisN, Gijsbers et al. LAAM maintenance vs methadone maintenance for heroid dependence. Cochrane Database Syst. Rev. (2) , CD002210 (2002).
  • Legarda JJ . Ultra-rapid opiate detoxification under anesthesia (UROD). Lancet351(9114) , 1517–1518 (1998).
  • Plunkett A , FahlgrenM, McLeanB, MundeyD. Opioid-free balanced anesthesia for cervical ganglionectomy subsequent to recent ultra rapid opioid detoxification. Pain Med.10(4) , 767–770 (2009).
  • Nasr DA , OmranHA, HakimSM, MansourWA. Ultra-rapid opiate detoxification using dexmedetomidine under general anesthesia. J. Opioid Manag.7(5) , 337–344 (2011).
  • Kleber H . Ultrarapid opiate detoxification. Addiction93 , 1629–1633 (1998).
  • Hamilton RJ , OlmedoRE, ShahS et al. Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets. Acad. Emerg. Med. 9 , 63–68 (2002).
  • Whittington RA , CollinsED, KleberHD. Rapid opioid detoxification during general anesthesia: is death not a significant outcome? Anesthesiology931 , 1363–1364 (2000).
  • Pfab R , HirtlC, ZilkerT. Opiate detoxification under anesthesia: no apparent benefit but suppression of thyroid hormones and risk of pulmonary and renal failure. J. Toxicol. Clin. Toxicol.37 , 43–50 (1999).
  • Shreeram SS , McDonaldT, DennisonS. Psychosis after ultrarapid opiate detoxification. Am. J. Psychiatry158 , 970 (2001).
  • Bell JR , YoungMR, MastermanSC, MorrisA, MattickRP, BammerG. A pilot study of naltrexone-accelerated detoxification in opioid dependence. Med. J. Aust.171 , 26–30 (1999).
  • Golden SA , SakhraniDL. Unexpected delirium during rapid opioid detoxification (ROD). J. Addict. Dis.23 , 65–75 (2004).
  • Cucchia AT , MonnatM, SpagnoliJ, FerreroF, BertschyG. Ultra-rapid opiate detoxification using deep sedation with oral midazolam: short and long-term results. Drug Alcohol Depend.52 , 243–250 (1998).
  • Gold CG , CullenDJ, GonzalesS, HoutmeyersD, DwyerMJ. Rapid opioid detoxification during general anesthesia: a review of 20 patients. Anesthesiology91 , 1639–1647 (1999).
  • Brewer C . Rapid opiate detoxification under anesthesia. Hosp. Med.60 , 70 (1999).
  • Collins ED , KleberHD, WhittingtonRA, HeitlerNE. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. JAMA294(8) , 903–913 (2005).
  • O‘Connor PG . Methods of detoxification and their role in treating patients with opioid dependence. JAMA294(8) , 961–963 (2005).
  • Sigmon SC , BisagaA, NunesEV, O‘ConnorPG, KostenT, WoodyG. Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice. Am. J. Drug Alcohol Abuse38(3) , 187–199 (2012).
  • Gowing L , FarrellM, AliR, WhiteJM. α2 adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst. Rev. (4) , CD002024 (2008).
  • Smith RJ , Aston-JonesG. Noradrenergic transmission in the extended amygdala: role in increased drug-seeking and relapse during protracted drug abstinence. Brain Struct. Funct.213 , 43–61 (2008).
  • Hall JE , UhrichTD, EbertTJ. Sedative, analgesic and cognitive effects of clonidine infusions in humans. Br. J. Anaesth.86 , 5–11 (2001).
  • Strain EC . Pharmacology and clinical use of LAAM, clonadine and lofexidine. In: The Treatment of Opioid Dependence. Strain EC, Stitzer ML (Eds). Johns Hopkins University Press, MD, USA, 275–294 (2006).
  • Buntwal N , BearnJ, GossopM, StrangJ. Naltrexone and lofexidine combination treatment compared with conventional lofexidine treatment for in-patient opiate detoxification. Drug Alcohol Depend.59(2) , 183–188 (2000).
  • Bearn J , GossopM, StrangJ. Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for in-patient opiate detoxification. Drug Alcohol Depend.50(3) , 227–232 (1998).
  • Strang J , BearnJ, GossopM. Lofexidine for opiate detoxification: review of recent randomised and open controlled trials. Am. J. Addict.8(4) , 337–348 (1999).
  • Alimi D , RubinoC, Pichard-LeandriE, Fermand-BruleS, Dubreuil-LemaireML, HillC. Analgesic effect of auricular acupuncture for cancer pain: a randomized, blinded, controlled trial. J. Clin. Oncol.21 , 4120–4126 (2003).
  • Simmons M , OlesonT. Auricular electrical stimulation and dental pain threshold. Anesth. Prog.40 , 14–19 (1993).
  • Wang SM , PeloquinC, KainZN. The use of auricular acupuncture to reduce preoperative anxiety. Anesth. Analg.93 , 178–180 (2001).
  • Taguchi A , SharmaN, AliSZ, DaveB, SesslerDI, KurzA. The effect of auricular acupuncture on anaesthesia with desflurane. Anaesthesia57 , 1159–1163 (2002).
  • Usichenko TI , DinseM, HermsenM, WitstruckT, PavlovicD, LehmannCH. Auricular acupuncture for pain relief after total hip arthroplasty – a randomized controlled study. Pain114 , 320–327 (2005).
  • Bradnam LV . A biopsychosocial clinical reasoning model for Western acupuncture. Phys. Ther. Rev.16(2) , 138–146 (2011).
  • Raith W , DutscheraJ, MullerW, UrlesbergerB. Active ear acupuncture points in neonates with neonatal abstinence syndrome (NAS). Am. J. Chinese Med.39(1) , 29–37 (2011).
  • D‘alberto A . Auricular acupuncture in the treatment of cocaine/crack abuse: a review of the efficacy, the use of the National Acupuncture Detoxification Association protocol, and the selection of sham points. J. Altern. Complement. Med.10(6) , 985–1000 (2004).
  • Stuyt EB , MeekerJL. Benefits of auricular acupuncture in tobacco-free inpatient dual-diagnosis treatment. J. Dual Diag.2(4) , 41–52 (2006).
  • Berman AH , LundbergUU. Auricular acupuncture in prison psychiatric units: a pilot study. Acta Psychiatr. Scand.106 , 152–257 (2002).
  • Patrick PKS . Stress-induced challenges to the counselor role: burnout, compassion fatigue, and vicarious traumatization. In: Contemporary Issues in Counseling. Patrick PKS (Ed.). Pearson Education, Boston, MA, USA, 210–250 (2007)
  • Levran O , YuferovV, KreekMJ. The genetics of the opioid system and specific drug addictions. Hum. Genet.131(6) , 823–842 (2012).
  • Oertel BG , DoehringA, RoskamB et al. Genetic-epigenetic interaction modulates µ-opioid receptor regulation. Hum. Mol. Genet. 21(21) , 4751–4760 (2012).
  • Chu LF , LiangDY, LiX et al. From mouse to man: the 5-HT3 receptor modulates physical dependence on opioid narcotics. Pharmacogenet. Genomics 19(3) , 193–205 (2009).
  • Doehring A , HentigNV, GraffJ et al. Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution. Pharmacogenet. Genomics 19(6) , 407–414 (2009).
  • Hall AJ , LoganJE, ToblinRL et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 300(22) , 2613–2620 (2008).

▪ Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.